HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nestlé Spies APAC Expansion Potential With Deal for New Zealand's Better Health

Executive Summary

Nestlé Health Science continues to expand its dietary supplements offering in 2022 penning a deal for New Zealand's The Better Health Company and its GO Healthy brand. The company says the deal will strengthen its presence not just in New Zealand but across the wider APAC region in markets such as Australia and China.

You may also be interested in...



Nestlé Expects Continued Supplement Demand Post-Pandemic

Nestlé CEO Mark Schneider says the company's consumer research indicates that the increase in dietary supplement usage over the past couple of years will endure post-pandemic. This continued demand help to lift sales at the company's Health Science business in the first half.

Nestlé Broadens Supplements Offering In Brazil With Puravida Acquisition

Nestlé Health Science is expanding its offering in Brazil with the acquisition of dietary supplements and nutritional products player Puravida.

Nestlé Health Science Beats Expectations In Q1

Nestlé Health Science beat management's expectations in Q1 to post a solid organic sales rise despite facing a high comparative with the prior-year period. While Nestlé's group-wide sales were up in the three months, CEO Mark Schneider warned that further price rises were coming down the track, which would inevitably impact consumer spending.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS152675

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel